Treatment of patients initially for acute deep vein thrombosis with a low-molecular-weight heparin at a fixed, body weight-independent dosage

Documenti analoghi

• Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin
  di: Harenberg, Job, et al.
  Pubblicazione: (2003)
• Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis
  di: Riess, Hanno, et al.
  Pubblicazione: (2003)
• Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin
  di: Harenberg, Job, et al.
  Pubblicazione: (2001)
• Biosimilars of low-molecular-weight heparin products: fostering competition or reducing ‘biodiversity’?
  di: Harenberg, Job
  Pubblicazione: (2016)
• Is laboratory monitoring of low-molecular-weight heparin therapy necessary?: yes
  di: Harenberg, Job
  Pubblicazione: (2004)